Wandercraft has raised $75 million in equity and debt to accelerate the launch of Eve, its self-balancing personal exoskeleton slated for 2026, expand clinical adoption of Atalante X, and advance industrial development of its humanoid robot, Calvin-40. The Series D round included participation from Renault Group, the French State-backed PSIM fund via Bpifrance, Teampact Ventures, and Quadrant Management. Renault Group has also become a minority stakeholder and will assist in scaling up production. Matthieu Masselin, CEO and Co-founder of Wandercraft, stated, “This funding allows us to continue our mission of transforming how people live, move, and work across rehabilitation, home environments, and soon on factory floors.”
The financing follows strong growth since Wandercraft’s previous $45 million Series C round, which fueled U.S. expansion and led to a tenfold revenue increase. The company’s technologies are deployed in over 100 rehabilitation centers, with Atalante X receiving two FDA clearances and helping over 2,500 individuals. Paul-François Fournier, Executive Director of Bpifrance, said that the investment will support broader access to Wandercraft’s robotic solutions, adding, “This Series D alongside Renault Group will enable the company to accelerate the industrial deployment of its unique robotics technology and make the Eve exoskeleton accessible to as many people as possible. Access to health and mobility for all is indeed a strategic focus supported by the French State through the France 2030 plan.”
